All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
During the 12th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-12), the Lymphoma Hub was pleased to speak to Anne Marie Becking and Wouter Verhaar, Amsterdam UMC, Amsterdam, NL. We asked them about their highlights from the workshop and their areas of clinical interest in Waldenstrom’s macroglobulinemia (WM).
IWWM-12: Highlights from young investigator research
In this interview, recorded at IWWM-12, Anne-Marie Becking and Wouter Verhaar, both medical doctors undertaking PhDs, discuss their research and clinical interests in WM. Verhaar focuses on the complexity of WM, particularly the role of IgM, its structural variations, and complications such as amyloidosis, aiming to explore new treatment options. He also highlights the collaborative spirit of the conference as a key benefit for young researchers. Becking specializes in glutenin disease, studying clonal characterization in the bone marrow, and conducts qualitative research through the WM-VOICE study, which evaluates patient preferences for treatment. Becking closes by emphasizing the value of the conference in showcasing global efforts toward WM therapies, highlighting the importance of translating research into patient-centered care.
This educational resource was independently supported by BeiGene. All content was developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox